Oricula Therapeutics is focused on developing innovative therapies to prevent drug-induced hearing loss, particularly from aminoglycoside antibiotics, which are essential for treating severe bacterial infections. Their lead product, ORC-13661, aims to protect the delicate hair cells in the inner ear that are crucial for hearing and balance. These hair cells do not regenerate once lost, making their preservation vital. ORC-13661 has successfully completed Phase 1 clinical trials, demonstrating safety, tolerability, and favorable pharmacokinetics, including a long half-life that allows for once-daily oral dosing. The compound has shown promise in preclinical studies, effectively protecting against hearing loss in animal models without interfering with the antibiotics' efficacy.

The research underpinning Oricula's technology leverages insights from studies on zebrafish, which share significant biological similarities with human inner ear hair cells. This model has enabled the identification of compounds that can safeguard these cells from ototoxic damage. ORC-13661 was developed through a systematic chemistry approach, resulting in a compound that is over 25 times more potent than its predecessor, ORC-0001. The company has secured intellectual property rights for ORC-13661, ensuring its exclusive development and commercialization across major global markets. As Oricula Therapeutics advances toward Phase 2 clinical trials, it aims to establish the efficacy of ORC-13661 in preserving hearing during aminoglycoside therapy.

United States

Working to develop drugs that reducing or eliminatehearing loss due to aminoglycoside therapy.

Oricula Therapeutics

Company Details